MIMABS

MImAbs is an R&D Platform for the generation and characterization of immunotherapy antibodies. By converting the most promising targets from academia, start-ups and industry into drug candidates and developing cutting-edge immunotechnologies, MImAbs allows research institutions, public technology transfer offices, biotech and biopharma companies to de-risk the development of next generation immunotherapies against cancer and inflammatory diseases, keeping one step ahead of the competition... MImAbs was created as an independent company in December 2020 by the acquisition of the assets of the demonstrator of immunotherapy MI-mAbs, founded in 2011, an academic laboratory of Aix-Marseille University... At the interface of academic research and biopharmaceutical industry, Mi-mAbs is a platform for innovative services designed to accelerate the development of new antibody-based immunotherapies against cancer and inflammatory diseases.

Primary location: Marseille France